ADPT vs. TSHA, EDIT, CCCC, ITOS, LXEO, FATE, VYGR, ALVO, REPL, and ALLO
Should you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Taysha Gene Therapies (TSHA), Editas Medicine (EDIT), C4 Therapeutics (CCCC), iTeos Therapeutics (ITOS), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Voyager Therapeutics (VYGR), Alvotech (ALVO), Replimune Group (REPL), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
Adaptive Biotechnologies (NASDAQ:ADPT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.
Taysha Gene Therapies has lower revenue, but higher earnings than Adaptive Biotechnologies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Adaptive Biotechnologies has a net margin of -123.24% compared to Taysha Gene Therapies' net margin of -722.06%. Taysha Gene Therapies' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.
99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 5.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Adaptive Biotechnologies presently has a consensus price target of $6.80, suggesting a potential upside of 78.95%. Taysha Gene Therapies has a consensus price target of $6.88, suggesting a potential upside of 186.46%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Adaptive Biotechnologies.
Adaptive Biotechnologies has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.
In the previous week, Adaptive Biotechnologies had 14 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 19 mentions for Adaptive Biotechnologies and 5 mentions for Taysha Gene Therapies. Adaptive Biotechnologies' average media sentiment score of 0.36 beat Taysha Gene Therapies' score of 0.32 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
Adaptive Biotechnologies received 6 more outperform votes than Taysha Gene Therapies when rated by MarketBeat users. However, 73.28% of users gave Taysha Gene Therapies an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.
Summary
Adaptive Biotechnologies beats Taysha Gene Therapies on 10 of the 18 factors compared between the two stocks.
Get Adaptive Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptive Biotechnologies Competitors List
Related Companies and Tools
